Trial · NCT00780962
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
NCT00780962, Phase 2, Completed, Beth Israel Deaconess Medical Center; results first posted 2018-01-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients. Trials, record NCT00780962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00780962
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
- NCT number
- NCT00780962
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 399 participants, actual
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Radiocontrast Nephropathy
- Interventions
- N-Acetylcysteine (NAC), 0.9% Sodium-chloride
- First posted
- 2008-10-28
- Last updated
- 2024-10-29
- Results first posted
- 2018-01-31
- Limitations and caveats
- Our results were obtained in patients considered to be at relatively low risk for contrast-induced nephropathy and should not be extended to patients who might be at higher risk for it.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Contrast-induced Nephropathy | 48-72 hours | Contrast-induced nephropathy was defined as an increase in serum creatinine level of greater than or equal to 0.5 mg/dL or an increase of 25% above baseline. The primary outcome was measured by the change in serum creatinine level from the pre-radiocontrast baseline to the serum creatinine level measured 48 to 72 hours after radiocontrast administration. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Contrast-induced Nephropathy | 48-72 hours | Out of 399 subjects who consented to participate in the study, only 357 (89.4%) had a second blood creatinine levels measurement done between 48 to 72h. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Contrast-induced Nephropathy | N-Acetycysteine Group | 14 | Participants | ||
| Number of Participants With Contrast-induced Nephropathy | 0.9% Sodium-chloride Group | 12 | Participants |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | N-Acetycysteine Group | 200 | |
| Overall Study | STARTED | 0.9% Sodium-chloride Group | 199 | |
| Overall Study | Second Blood Draw (Outcome Measurement) | N-Acetycysteine Group | 185 | |
| Overall Study | Second Blood Draw (Outcome Measurement) | 0.9% Sodium-chloride Group | 172 | |
| Overall Study | COMPLETED | N-Acetycysteine Group | 185 | |
| Overall Study | COMPLETED | 0.9% Sodium-chloride Group | 172 | |
| Overall Study | NOT COMPLETED | N-Acetycysteine Group | 15 | |
| Overall Study | NOT COMPLETED | 0.9% Sodium-chloride Group | 27 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Itching | Skin and subcutaneous tissue disorders | N-Acetycysteine Group | 1 | 200 | 1 |
| other | Itching | Skin and subcutaneous tissue disorders | 0.9% Sodium-chloride Group | 2 | 199 | 2 |
| other | Flushing | Skin and subcutaneous tissue disorders | N-Acetycysteine Group | 3 | 200 | 3 |
| other | Flushing | Skin and subcutaneous tissue disorders | 0.9% Sodium-chloride Group | 3 | 199 | 3 |
| other | Rash | Skin and subcutaneous tissue disorders | N-Acetycysteine Group | 1 | 200 | 1 |
| other | Rash | Skin and subcutaneous tissue disorders | 0.9% Sodium-chloride Group | 0 | 199 | 0 |
| other | Nausea | Gastrointestinal disorders | N-Acetycysteine Group | 4 | 200 | 4 |
| other | Nausea | Gastrointestinal disorders | 0.9% Sodium-chloride Group | 4 | 199 | 4 |
| other | Vomiting | Gastrointestinal disorders | N-Acetycysteine Group | 1 | 200 | 1 |
| other | Vomiting | Gastrointestinal disorders | 0.9% Sodium-chloride Group | 3 | 199 | 3 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | N-Acetycysteine Group | 0 | 200 |
| Total, all-cause mortality | 0.9% Sodium-chloride Group | 0 | 199 |
| Total, other adverse events | N-Acetycysteine Group | 13 | 200 |
| Total, other adverse events | 0.9% Sodium-chloride Group | 17 | 199 |
| Total, serious adverse events | N-Acetycysteine Group | 0 | 200 |
| Total, serious adverse events | 0.9% Sodium-chloride Group | 0 | 199 |
Source ClinicalTrials.gov
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| N-Acetycysteine Group vs 0.9% Sodium-chloride Group: Number of Participants With Contrast-induced Nephropathy | Trial comparisons |
| N-Acetycysteine Group vs 0.9% Sodium-chloride Group: deaths from any cause | Trial comparisons |
| N-Acetycysteine Group vs 0.9% Sodium-chloride Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00780962
GET https://conductscience.org/api/trials/v1/NCT00780962/registered